2
©
2015 Galectin Therapeutics | NASDAQ:GALT
Forward-Looking Statements
This presentation contains, in addition to historical information, forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements relate to future events or future financial performance, and use words
such as may, estimate, could, expect and others. They are based on our
current expectations and are subject to factors and uncertainties which could cause actual
results to differ materially from those described in the statements. These statements
include those regarding potential therapeutic benefits of our drugs, expectations,
plans and timelines related to our clinical trials, potential partnering opportunities
and estimated spending for 2015. Factors that could cause our actual performance to
differ materially from those discussed in the forward-looking statements include, among
others, our trials may not lead to positive outcomes or regulatory approval. We
may experience delays in our trials, which could include enrollment delays.
Future phases or future clinical studies may not begin or produce positive results in a timely
fashion, if at all, and could prove time consuming and costly. Plans regarding development,
approval and marketing of any of our drugs are subject to change at any time based on
the changing needs of our company as determined by management and regulatory agencies.
Strategies and spending projections may change. We may be unsuccessful in
developing partnerships with other companies or obtaining capital that would allow us to
further develop and/or fund any studies or trials. We are currently the subject of litigation,
which may impact our human and capital resources. To date, we have incurred operating
losses since our inception, and our future success may be impacted by our ability to
manage costs and finance our continuing operations. For a discussion of additional
factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31,
2013, and our subsequent filings with the SEC. You should not place undue reliance on
forward-looking statements. Although subsequent events may cause our views to
change, we disclaim any obligation to update forward-looking statements. |